Skip to main content
. 2021 Apr 22;13(9):2024. doi: 10.3390/cancers13092024

Figure 9.

Figure 9

IMC states dictate targeted drugging potency in BRAFV600D-dependent melanoma cells. (A–F) MTT assays in bar-chart format demonstrating survival percentages (%) of WM115 (primary) and WM266-4 (metastatic) human BRAFV600D-positive melanoma cells, in response to: (A) “LY-364947” (0–100 μM, for 48 h), (B) “Vinblastine” (0–100 μM, for 24 h), (C) “Cisplatin” (0–100 μg/mL, for 24 h), (D) “Paclitaxel” (0–100 μM, for 24 h), (E) “Sorafenib” (0–100 μM, for 24 h), and (F) “Epirubicin” (0–100 μM, for 24 h).